PMID- 23754536
OWN - NLM
STAT- MEDLINE
DCOM- 20140213
LR  - 20161125
IS  - 1791-3004 (Electronic)
IS  - 1791-2997 (Linking)
VI  - 8
IP  - 2
DP  - 2013 Aug
TI  - Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through 
      peroxisome proliferator-activated receptor-alpha activation.
PG  - 439-45
LID - 10.3892/mmr.2013.1512 [doi]
AB  - Non-alcoholic fatty liver disease (NAFLD) is the most common type of liver 
      disease worldwide. Recent studies have reported that oxymatrine (OMT), an active 
      monomer isolated from Sophora flavescens Ait. (kushen), ameliorates NAFLD in 
      rats. In order to explore the possible molecular mechanism involved, we used an 
      NAFLD rat model with hyperlipidemia, which had been established by feeding a 
      high‑fructose diet (HFD) for eight weeks, and the model rats were subsequently 
      treated with OMT (80 mg/kg/day) for a further four weeks. We evaluated the 
      expression of genes and proteins regulating fatty acid oxidation and lipid export 
      in the liver using quantitative (q)PCR and western blot analysis. The NAFLD model 
      rats developed dyslipidaemia, hepatic steatosis and insulin resistance (IR). OMT 
      administration for four weeks reduced body weight gain and visceral fat weight, 
      decreased serum triglyceride (TG), total cholesterol (TC), free fatty acid (FFA) 
      and fasting serum insulin (FinS) levels and lowered liver TG contents. It also 
      increased the glucose infusion rate (GIR), indicative of a reduction in IR. 
      Moreover, OMT treatment markedly increased the mRNA and protein levels of 
      peroxisome proliferator-activated receptor-alpha (PPARalpha), carnitine 
      palmitoyltransferase 1A (CPT1A) and microsomal triglyceride transfer protein 
      (MTTP). The beneficial effects of OMT were further confirmed by the observation 
      of a decrease in lipid accumulation in the histology of the liver. Our results 
      indicate that OMT may be used to treat NAFLD.
FAU - Shi, Lijuan
AU  - Shi L
AD  - Department of Internal Medicine, Hebei Medical University, Shijiazhuang 050017, 
      P.R. China.
FAU - Shi, Lei
AU  - Shi L
FAU - Zhang, Hefang
AU  - Zhang H
FAU - Hu, Zhijuan
AU  - Hu Z
FAU - Wang, Chao
AU  - Wang C
FAU - Zhang, Donghui
AU  - Zhang D
FAU - Song, Guangyao
AU  - Song G
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20130606
PL  - Greece
TA  - Mol Med Rep
JT  - Molecular medicine reports
JID - 101475259
RN  - 0 (Alkaloids)
RN  - 0 (Lipids)
RN  - 0 (PPAR alpha)
RN  - 0 (Quinolizines)
RN  - 85U4C366QS (oxymatrine)
SB  - IM
MH  - Alkaloids/administration & dosage/*pharmacology
MH  - Animals
MH  - Body Weight/drug effects
MH  - Disease Models, Animal
MH  - Fatty Liver/genetics/*metabolism
MH  - Insulin Resistance
MH  - Intra-Abdominal Fat/anatomy & histology/drug effects
MH  - Lipid Metabolism
MH  - Lipids/blood
MH  - Liver/drug effects/metabolism/pathology
MH  - Male
MH  - Non-alcoholic Fatty Liver Disease
MH  - Organ Size
MH  - PPAR alpha/*agonists/genetics/*metabolism
MH  - Quinolizines/administration & dosage/*pharmacology
MH  - Rats
EDAT- 2013/06/12 06:00
MHDA- 2014/02/14 06:00
CRDT- 2013/06/12 06:00
PHST- 2013/01/16 00:00 [received]
PHST- 2013/05/30 00:00 [accepted]
PHST- 2013/06/12 06:00 [entrez]
PHST- 2013/06/12 06:00 [pubmed]
PHST- 2014/02/14 06:00 [medline]
AID - 10.3892/mmr.2013.1512 [doi]
PST - ppublish
SO  - Mol Med Rep. 2013 Aug;8(2):439-45. doi: 10.3892/mmr.2013.1512. Epub 2013 Jun 6.